Spero closes $30M series B round

Anti-infective play Spero Therapeutics LLC (Cambridge, Mass.) secured $30 million in a tranched series B round from existing investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, the Kraft Group and Partners Innovation Fund. Spero raised $30 million from the syndicate in an A round announced in June (see BioCentury, June 15, 2015).

Spero is developing anti-infectives, including compounds that the company calls potentiators that aim to enhance the utility and potency of existing drugs to include Gram-negative organisms. President and CEO Ankit Mahadevia told BioCentury the funds should last through the initial safety data from a Phase I trial of its first potentiator. ...